EMA Withdrawn: Levviax (telithromycin) — Aventis Pharma S.A.

View source ↗

Summary

Telithromycin (Levviax) has been withdrawn from the market by Aventis Pharma S.A. for community-acquired infections including pharyngitis, bronchitis, pneumonia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis Chronic
• Pharyngitis
• Pneumonia
• Sinusitis
• Tonsillitis

Drugs mentioned

• Levviax (telithromycin)

Snippet

Status: Withdrawn. Therapeutic area: Community-Acquired Infections;Pharyngitis;Bronchitis, Chronic;Pneumonia;Tonsillitis;Sinusitis. MAH: Aventis Pharma S.A.. Decision date: 31/05/2007